IDS Form PTO/SB/08: Substitute for form 1449A/PTO		Complete if Known			
				Application Number	10/541,394
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	March 29, 2006
				First Named Inventor	Matti KIVIKKO
				Art Unit	1614
				Examiner Name	Christopher R. STONE
Sheet	1	of	1	Attorney Docket Number	06267.0128-00000

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.1	Number-Kind Code ² (# known) Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear		
		US-				
		US-				

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No 1	Foreign Patent Document Country Code ³ Number ³ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Trenslation ^b	

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1			
		Office Action dated June 16, 2009, for co-pending Application No. 11/355,896.		
		Advisory Action dated October 29, 2009, for co-pending Application No. 11/355,896.		
		Bellomo et al., "Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial," <i>The Lancet</i> , 356, December 23/30, pages 2139-2143.		
		Oldner et al., "Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock," Crit. Care Med., 29(11): 2185-2193 (2001).		

Examiner Date Signature Considered	
Signature	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.